MyFinsight
Home
Blog
About
Proceeds from
convertible promissory...
$950,000
Net cash provided by
financing activities
$950,000
(-89.27%↓ Y/Y)
Net change in cash
-$4,452,061
(-384.70%↓ Y/Y)
Canceled cashflow
$950,000
Reimbursement right asset
-$2,297,806
Non-cash transaction
costs
$280,000
Change in fair value of
contingent consideration
$217,000
Depreciation
$23,937
(-10.97%↓ Y/Y)
Pipe warrant
issuance cost
$9,534
Deferred tax liability
$300
Net cash used in
operating activities
-$5,402,061
(25.91%↑ Y/Y)
Canceled cashflow
$2,828,577
Net loss
-$6,750,127
(58.74%↑ Y/Y)
Prepaid expenses and
other current assets
$644,024
(208.88%↑ Y/Y)
Accounts payable and
accrued expenses
-$585,951
(48.74%↑ Y/Y)
Change in fair value of
warrant liabilities
-$229,221
(-102.44%↓ Y/Y)
Deferred grant income
-$21,315
(16.11%↑ Y/Y)
Back
Back
Cash Flow
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com